Original Article
¤ÇÒÁËÇÁÁ×Í㹡Òû¯ÔºÑµÔµ¹ÃÐËÇ‹Ò§¡ÒÃÃÑ¡ÉÒáÅÐ
¤Ø³ÀÒ¾ªÕÇÔµ¢Í§¼ÙŒ»†ÇÂÁÐàÃ秵‹ÍÁä·ÃÍ´
Treatment adherence and quality of life among thyroid cancer patients
¹ÄÀÑ ÊÁÄ´Õ
1ʧǹ Å×Íà¡ÕÂõԺѳ±Ôµ
2àµçÁÈÑ¡´Ôì ¾Öè§ÃÑÈÁÕ
1ÇѹªÑ ¸ÃÃÁÊѨ¡ÒÃ
3Naruepai Somruedee
1Sanguan Lerkiatbundit
2Temsak Phungrassami
1Wanchai Dhammasaccakarn
31ÀÒ¤ÇÔªÒÃѧÊÕÇÔ·ÂÒ ¤³Ðá¾·ÂÈÒʵà ÁËÒÇÔ·ÂÒÅÑ ʧ¢ÅÒ¹¤ÃÔ¹·Ã Í.ËÒ´ãËÞ‹ ¨.ʧ¢ÅÒ 90110
2ÀÒ¤ÇÔªÒºÃÔËÒÃàÀÊѪ¡Ô¨ ¤³ÐàÀÊѪÈÒʵÃ
3ÀÒ¤ÇÔªÒÊÒÃѵ¶ÈÖ¡ÉÒ ¤³ÐÈÔÅ»ÈÒʵÃ
ÁËÒÇÔ·ÂÒÅÑÂʧ¢ÅÒ¹¤ÃÔ¹·Ã Í.ËÒ´ãËÞ‹ ¨.ʧ¢ÅÒ 90112
1Department of Radiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand
2Department of Pharmacy Administration, Faculty of Pharmaceutical Sciences,
3Department of Education Foundation, Faculty of Liberal Arts,
Prince of Songkla University, Hat Yai, Songkhla, 90112, Thailand
E-mail: [email protected] Songkla Med J 2010;28(2):81-88
º·¤Ñ´Â‹Í:
¡ÒÃÇÔ¨ÑÂÁÕÇѵ¶Ø»ÃÐʧ¤à¾×èÍÈÖ¡ÉÒ 1) ¤ÇÒÁËÇÁÁ×Íã¹
¡Òû¯ÔºÑµÔµ¹ÃÐËÇ‹Ò§¡ÒÃÃÑ¡ÉҢͧ¼ÙŒ»†ÇÂÁÐàÃ秵‹ÍÁä·ÃÍ´
2) »˜¨¨Ñ·ÕèÁռŵ‹Í¤ÇÒÁËÇÁÁ×Í㹡Òû¯ÔºÑµÔµ¹´Ñ§¡Å‹ÒÇ 3) ¤Ø³ÀÒ¾ªÕÇÔµ¢Í§¼ÙŒ»†ÇÂÁÐàÃ秵‹ÍÁä·ÃÍ´¡‹Í¹-ËÅѧ
ÃѺ»ÃзҹäÍâÍ´Õ¹-131 ¡ÅØ‹ÁµÑÇÍ‹ҧ ¤×Í ¼ÙŒ·Õèŧ·ÐàºÕ¹ ÃÑ¡ÉÒÁÐàÃ秵‹ÍÁä·ÃÍ´´ŒÇÂÇÔ¸ÕäÍâÍ´Õ¹-131 ablation ã¹¢¹Ò´ 30 ÁÔÅÅÔ¤ÔÇÃÕ ·Õè˹‹ÇÂàǪÈÒʵùÔÇà¤ÅÕÂÃ
âç¾ÂÒºÒÅʧ¢ÅÒ¹¤ÃÔ¹·Ã ¨Ó¹Ç¹ 138 ÃÒ ¼ÙŒÇԨѠÊÑÁÀÒɳ¡ÅØ‹ÁµÑÇÍ‹ҧ 2 ¤ÃÑé§ Ë‹Ò§¡Ñ¹ 5-7 Çѹ Ẻ ÊÑÁÀÒɳ¨Ñ´·Óâ´Â¼ÙŒÇԨѠ»ÃСͺ´ŒÇÂẺÇÑ´¤ÇÒÁÃÙŒ à¡ÕèÂǡѺ¡ÒÃÃÑ¡ÉÒ ¡Òû¯ÔºÑµÔµ¹ áÅСÒÃÅ´¡ÒÃἋ
¡ÃШÒÂÃѧÊÕ »˜¨¨Ñ´ŒÒ¹¡ÒÃÃѺÃÙŒ áÅФÇÒÁËÇÁÁ×Í㹡ÒÃ
»¯ÔºÑµÔµ¹µÒÁ¤Óá¹Ð¹Ó ¡ÒÃÇÑ´¤Ø³ÀÒ¾ªÕÇԵ㪌ẺÇÑ´
The Functional Assessment of Cancer Therapy- General (FACT-G) ©ºÑºÀÒÉÒä·Â
¼ÙŒ»†ÇÂÊÒÁÒö»¯ÔºÑµÔµ¹¡‹Í¹-ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 áÅСÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕµÒÁ¤Óá¹Ð¹Ó䴌͋ҧ
¶Ù¡µŒÍ§ÁÒ¡¡Ç‹ÒÃŒÍÂÅÐ 90 µÑÇá»Ã·Õè·ÓãËŒÁÕ¤ÇÒÁËÇÁÁ×Í ã¹¡Òû¯ÔºÑµÔµ¹¡‹Í¹ÃѺ»ÃзҹäÍâÍ´Õ¹-131 ¤×Í ¤ÇÒÁÃÙŒ àÃ×èͧ¡Òû¯ÔºÑµÔµ¹ ¡Òü‹Ò¹¡ÒÃÃÑ¡ÉÒ´ŒÇÂäÍâÍ´Õ¹-131 ÁÒ¡‹Í¹áÅСÒÃÈÖ¡ÉÒµÑÇá»Ã·Õè·ÓãËŒÁÕ¤ÇÒÁËÇÁÁ×Í㹡ÒÃ
»¯ÔºÑµÔµ¹ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 ¤×Í ¤ÇÒÁÃÙŒàÃ×èͧ
ÇÔ¸Õ»¯ÔºÑµÔµ¹ áÅСÒÃÈÖ¡ÉÒ Ê‹Ç¹µÑÇá»Ã·Õè·ÓãËŒÁÕ¤ÇÒÁ ËÇÁÁ×Í㹡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕ ¤×Í ¤ÇÒÁÃÙŒã¹ÇÔ¸Õ¡ÒÃ
»¯ÔºÑµÔµ¹ ¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹Êѧ¤Á/¤Ãͺ¤ÃÑÇ áÅФÇÒÁ
¼ÒÊØ¡·Ò§´ŒÒ¹ÍÒÃÁ³ ¨Ôµã¨ÁÕ¤‹Òà»ÅÕè¹á»Å§ä»Í‹ҧÁÕ
¹ÑÂÊÓ¤Ñ޷ҧʶԵÔËÅѧ¨Ò¡ÃѺ»Ãзҹ I-131
¤ÓÊÓ¤ÑÞ: ¤Ø³ÀÒ¾ªÕÇÔµ, ¤ÇÒÁËÇÁÁ×Í㹡Òû¯ÔºÑµÔµ¹, ÁÐàÃ秵‹ÍÁä·ÃÍ´
ÃѺµŒ¹©ºÑºÇѹ·Õè 7 µØÅÒ¤Á 2552 ÃѺŧµÕ¾ÔÁ¾Çѹ·Õè 8 ¡ØÁÀҾѹ¸
2553
Abstract:
This study aimed to 1) determine the rate of adherence to treatment recommendations from health professionals among thyroid cancer patients, 2) identify factors infl uencing the adherence, and 3) compare the quality of life among patients before and after treatment with 30 mCi. radioiodine-131 (I-131). One hundred thirty eight patients who were registered at the Nuclear Medicine Division, Songklanagarind Hospital and received I-131 ablation were enrolled in the study. The researcher inter- viewed the subjects on two occasions 5-7 days apart. Two instruments were used in the study: The Functional Assessment of Cancer Therapy (FACT-G) instrument for assessing the patients’ quality of life and the interview instrument developed specifi cally for the study to measure knowledge on treatment recom- mendation, knowledge on treatment, relevant health beliefs, and adherence to the treatment recommendation from health professionals.
The results showed that more than 90% of patients followed the advice of health pro- fessionals on how to follow safety precautions before and after I-131 ingestion, and how to reduce radiation risk to others. The signifi cant predictors of adherence to the recommen- dations of safety precautions before receiving I-131 were knowledge of the correct practices, education, and experiences with treatment. The factors affecting adherence to the recommen- dation of safety precautions after receiving I-131 were knowledge on safety precautions, and education. The only signifi cant predictor of adherence to the recommendation to reduce radiation was knowledge on safety precautions.
The social/family well-being significantly decreased, but emotional well-being signifi - cantly improved after I-131 treatment.
Key words: quality of life, thyroid cancer, treat- ment adherence
º·¹Ó
¨Ò¡ÃÒ§ҹ¢Í§âç¾ÂÒºÒÅʧ¢ÅÒ¹¤ÃÔ¹·Ã ã¹»‚ ¾.È.2549 ÁÕ¼ÙŒ»†ÇÂÁÐàÃ秵‹ÍÁä·ÃÍ´ãËÁ‹ 227 ÃÒ ¹Ñºà»š¹
Íѹ´Ñº 7 ¢Í§ÁÐàÃ秷Õ辺ã¹âç¾ÂÒºÒÅʧ¢ÅÒ¹¤ÃÔ¹·Ã1 ÇÔ¸Õ¡ÒÃÃÑ¡ÉÒÁÐàÃ秵‹ÍÁä·ÃÍ´Ẻ˹Öè§ ¤×Í ¡ÒÃÃÑ¡ÉÒ
´ŒÇÂäÍâÍ´Õ¹-131 ablation ¢¹Ò´ 30 ÁÔÅÅÔ¤ÔÇÃÕ áÅР͹ØÞÒµãËŒ¼ÙŒ»†Ç¡ÅѺ仾ӹѡ·Õ躌ҹ䴌 â´Â»¯ÔºÑµÔµÒÁ
¢ŒÍ¡Ó˹´¢Í§ Nuclear Regulatory Commission (NRC) ¤×Í ¼ÙŒ»†ÇÂáÅмٌ´Ùáżٌ»†Ç¨Ðä´ŒÃѺ¤Óá¹Ð¹Ó ã¹àÃ×èͧ¡Òû¯ÔºÑµÔµÑÇà¾×èÍ»‡Í§¡Ñ¹¡ÒÃà»ÃÍÐໄœÍ¹ÃѧÊÕ ËÃ×ÍãËŒ¼ÙŒã¡ÅŒªÔ´ä´ŒÃѺÃѧÊÕ¹ŒÍ·ÕèÊØ´2
¡ÒÃäÁ‹»¯ÔºÑµÔµ¹µÒÁ¤Óá¹Ð¹Ó¡‹Í¹ÃѺ»Ãзҹ äÍâÍ´Õ¹-131 䴌ᡋ äÁ‹ËÂØ´ÂÒÎÍÃâÁ¹ä·ÃÍ´ äÁ‹§´
ÍÒËÒ÷ÐàÅ äÁ‹§´ãËŒ¹ÁºØµÃ ¡ÒõÑ駤ÃÃÀ äÁ‹ÁÒÃѺ
¡ÒÃÃÑ¡ÉҵçÇѹ¹Ñ´ ໚¹µŒ¹ ÁÕ¼ÅàÊÕ·ÓãËŒ¼ÙŒ»†ÇÂäÁ‹ä´Œ ÃѺ¡ÒÃÃÑ¡ÉÒµÒÁá¼¹ «Öè§ÍҨʋ§¼Åµ‹Í¡ÒÃÅØ¡ÅÒÁ¢Í§
ÁÐàÃ秵‹ÍÁä·ÃÍ´ áÅеŒÍ§»Å‹ÍÂãËŒäÍâÍ´Õ¹-131 ·Õè
¨Ñ´àµÃÕÂÁäÇŒÊÓËÃѺ¼ÙŒ»†ÇÂᵋÅÐÃÒÂÊÅÒµÑÇä»â´Âà»Å‹Ò
»ÃÐ⪹à¾ÃÒÐäÁ‹ÊÒÁÒö¨Ñ´ËÒ¼ÙŒ»†ÇÂÃÒÂÍ×è¹ÁÒ·´á·¹ ä´Œ·Ñ¹ ¡ÒÃäÁ‹»¯ÔºÑµÔµ¹ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 Ê‹§¼Å¡Ãзº´ŒÒ¹¤ÇÒÁ»ÅÍ´ÀÑ·ҧÃѧÊÕµ‹ÍºØ¤¤ÅÍ×è¹·Õè ÍÂÙ‹ã¡ÅŒªÔ´ â´Â੾ÒÐÍѹµÃÒ·ÕèÍÒ¨¨Ðà¡Ô´¡Ñºà´ç¡áÅРʵÃÕµÑ駤ÃÃÀ ¹Í¡¨Ò¡¹Õéã¹ÃÐËÇ‹Ò§·Ó¡ÒÃÃÑ¡ÉÒ¼ÙŒ»†Ç µŒÍ§á¡µÑÇÍÂÙ‹µÒÁÅӾѧ “ª‹Ç§ÃÐÇѧÃѧÊÕ” »ÃÐÁÒ³ ˹Öè§ÊÑ»´ÒË ÍҨʋ§¼Å¡Ãзºµ‹Í¤Ø³ÀÒ¾ªÕÇÔµ¢Í§¼ÙŒ»†ÇÂ
·Ñ駴ŒÒ¹Ã‹Ò§¡Ò ´ŒÒ¹¨Ôµã¨ ÍÒÃÁ³ ´ŒÒ¹¤ÇÒÁÊÑÁ¾Ñ¹¸
·Ò§Êѧ¤Á ¤Ãͺ¤ÃÑÇ áÅдŒÒ¹»¯ÔºÑµÔ¡Ô¨¡ÃÃÁ
§Ò¹ÇԨѹÕéà¾×èÍÈÖ¡ÉÒ»˜¨¨Ñ·ÕèÁռŵ‹Í¡Òû¯ÔºÑµÔµ¹ µÒÁ¤Óá¹Ð¹Ó ¡‹Í¹-ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 áÅÐ
¡Òû¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒ¢ͧÃѧÊÕ «Öè§
¢ŒÍÁÙÅ·Õèä´Œ¨Ð໚¹»ÃÐ⪹µ‹Í¡ÒûÃѺ»Ãاá¹Ç·Ò§
¡ÒôÙáżٌ»†ÇÂÁÐàÃ秵‹ÍÁä·ÃÍ´
ÇÑÊ´ØáÅÐÇÔ¸Õ¡ÒÃ
¼ÙŒ»†ÇÂâäÁÐàÃ秵‹ÍÁä·ÃÍ´·Õè¹Ñ´ÁÒÃѺ»Ãзҹ äÍâÍ´Õ¹-131 ¢¹Ò´ 30 ÁÔÅÅÔ¤ÔÇÃÕ áÅÐÂÔ¹ÂÍÁà¢ŒÒ Ã‹ÇÁâ¤Ã§¡ÒÃÇÔ¨ÑÂÃÑ¡ÉÒ·Õè˹‹ÇÂàǪÈÒʵùÔÇà¤ÅÕÂÃ
âç¾ÂÒºÒÅʧ¢ÅÒ¹¤ÃÔ¹·Ã µÑé§áµ‹¾ÄȨԡÒ¹ ¾.È.
2551 - ÁÕ¹Ò¤Á ¾.È. 2552 ä
â¤Ã§Ã‹Ò§¡ÒÃÇÔ¨ÑÂä´Œ¼‹Ò¹¡ÒÃ͹ØÞÒµ¨Ò¡¤³Ð ͹ءÃÃÁ¡ÒþԨÒóҨÃÔ¸ÃÃÁ´ŒÒ¹ÇÔ¨ÑÂà¡ÕèÂǡѺ¡Òà ºÃÔºÒżٌ»†Ç ÊÔè§Ê‹§µÃǨ áÅÐÊѧ¤ÁÈÒʵáÒÃá¾·Â
¤³Ðá¾·ÂÈÒʵá‹Í¹¡ÒÃà¡çº¢ŒÍÁÙÅ
㪌ẺÊͺ¶ÒÁ·ÕèÊÌҧ¢Öé¹àͧáÅÐ㪌 The Func- tional Assessment of Cancer Therapy (FACT-G) version 4 ©ºÑºá»Åä·Â3 ä´Œ¹ÓẺÊͺ¶ÒÁä»
·´Êͺ¤ÇÒÁµÃ§´ŒÒ¹à¹×éÍËÒ ·´Êͺ¤ÇÒÁà·Õ觵ç
áÅФÇÒÁàª×èÍÁÑè¹à»š¹ÃÒµÑÇá»Ã â´ÂÇÔ¸Õ¡ÒÃËÒ¤ÇÒÁ ÊÍ´¤ÅŒÍ§ÀÒÂã¹â´Â¤Ó¹Ç³¤‹ÒÊÑÁ»ÃÐÊÔ·¸ÔìáÍÅ¿†Ò
¢Í§¤Ã͹ºÒ¤ (Cronbach’s alpha coeffi cient) áÅÐÇÔ¸Õ Test-Retest ÁÕ¤ÇÒÁà·Õè§ã¹ÃдѺ·Õ蹋ҾÍã¨
â´ÂÁÕ¤‹ÒÁÒ¡¡Ç‹Ò 0.70 ¡àÇŒ¹¡ÒÃÃѺÃÙŒÍØ»ÊÃä¢Í§¡ÒÃ
»¯ÔºÑµÔµÒÁ¤Óá¹Ð¹Ó¡è͹ÃѺ»ÃзҹäÍâÍ´Õ¹-131
¤ÇÒÁÃÙŒàÃ×èͧ¡Òû¯ÔºÑµÔµ¹¡‹Í¹ÃѺ»ÃзҹäÍâÍ´Õ¹-131 áÅФÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹Êѧ¤Á/¤Ãͺ¤ÃÑÇ ä´Œ¤‹Ò 0.586, 0.667 áÅÐ 0.679 µÒÁÅӴѺ
¡ÒÃà¡çºÃǺÃÇÁ¢ŒÍÁÙÅ
ÊÑÁÀÒɳ¡ÅØ‹ÁµÑÇÍ‹ҧ´ŒÇµ¹àͧ ᵋÅÐÃÒ¨Р䴌ÃѺ¡ÒÃÊÑÁÀÒɳ 2 ¤ÃÑé§ ¼ÙŒ»†ÇÂà¡‹ÒáÅÐãËÁ‹·Õè¹Ñ´
ÁÒÃѺ»ÃзҹäÍâÍ´Õ¹-131 ¢¹Ò´ 30 ÁÔÅÅÔ¤ÔÇÃÕ ·Ø¡ÃÒÂ
¨Ðä´ŒÃѺ¡ÒÃÊÑÁÀÒɳã¹àÃ×èͧ á¹Ç¤Ó¶ÒÁà¡ÕèÂǡѺ
¢ŒÍÁÙÅ·ÑèÇä» ¡Òû¯ÔºÑµÔµ¹¡‹Í¹ÃѺ»ÃзҹäÍâÍ´Õ¹- 131 ẺÇÑ´¤ÇÒÁÃÙŒàÃ×èͧâäÁÐàÃ秵‹ÍÁä·ÃÍ´ »˜¨¨ÑÂ
´ŒÒ¹¡ÒÃÃѺÃÙŒ»ÃÐ⪹¢Í§¡Òû¯ÔºÑµÔ ¡ÒÃÃѺÃÙŒÍØ»ÊÃä
¢Í§¡Òû¯ÔºÑµÔ áÅСÒÃÃѺÃÙŒâÍ¡ÒÊàÊÕè§ÍѹµÃÒÂËÒ¡äÁ‹
»¯ÔºÑµÔµÒÁ¤Óá¹Ð¹Ó ẺÊͺ¶ÒÁ¤Ø³ÀÒ¾ªÕÇÔµ¼ÙŒ»†ÇÂ
¡‹Í¹ÃѺ»ÃзҹäÍâÍ´Õ¹-131 áÅйѴãËŒÁÒµÃǨÊ᡹ ÀÒÂã¹ 5-7 Çѹ ã¹Çѹ·ÕèÁÒÃѺ¡ÒõÃǨÊ᡹ÀÒÂËÅѧ
¨Ò¡µÃǨÊ᡹àÊÃ稼ٌÇԨѨÐÊÑÁÀÒɳ¼ÙŒ»†ÇÂã¹àÃ×èͧ
á¹Ç¤Ó¶ÒÁà¡ÕèÂǡѺ¢ŒÍÁÙÅ·ÑèÇä» ¡Òû¯ÔºÑµÔµ¹´ŒÒ¹ ÊØ¢ÀÒ¾ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 ¡Òû¯ÔºÑµÔµ¹
´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕ áººÇÑ´¤ÇÒÁÃÙŒàÃ×èͧ¡Òà ÃÑ¡ÉÒâäÁÐàÃ秵‹ÍÁä·ÃÍ´ÀÒÂËÅѧÃѺ»Ãзҹ
äÍâÍ´Õ¹-131 áÅСÒÃÅ´¡ÒÃἋ¡ÃШÒ¢ͧÃѧÊÕ »˜¨¨ÑÂ
´ŒÒ¹¡ÒÃÃѺÃÙŒ´ŒÒ¹ÊØ¢ÀÒ¾áÅÐÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕ (¡ÒÃÃѺÃÙŒ»ÃÐ⪹¢Í§¡Òû¯ÔºÑµÔ ¡ÒÃÃѺÃÙŒÍØ»ÊÃä¢Í§
¡Òû¯ÔºÑµÔ áÅСÒÃÃѺÃÙŒâÍ¡ÒÊàÊÕè§ÍѹµÃÒÂËÒ¡äÁ‹
»¯ÔºÑµÔµÒÁ¤Óá¹Ð¹Ó) ¤Ø³ÀÒ¾ªÕÇÔµ¼ÙŒ»†ÇÂËÅѧÃѺ
»ÃзҹäÍâÍ´Õ¹-131
ẺÇÑ´¤ÇÒÁÃÙŒ¨Ð»ÃСͺ¤Ó¶ÒÁ·Õè·´ÊͺNjҼٌ»†Ç ÁÕ¤ÇÒÁÃÙŒ ¤ÇÒÁࢌÒã¨à¡ÕèÂǡѺ¡ÒÃÃÑ¡ÉÒ áÅл¯ÔºÑµÔµ¹ ËÃ×ÍäÁ‹ Í‹ҧäà ʋǹẺÊͺ¶ÒÁà¡ÕèÂǡѺ¡Òû¯ÔºÑµÔµ¹
¨Ð์¹Ç‹Ò¼ÙŒ»†ÇÂä´Œ»¯ÔºÑµÔ¾ÄµÔ¡ÃÃÁ¹Ñ鹨ÃÔ§ËÃ×ÍäÁ‹
à¾×èÍãˌ䴌¤ÓµÍºÁÕ¤ÇÒÁ¹‹Òàª×èÍ ¼ÙŒÇÔ¨ÑÂ㪌ẺÇÑ´¤ÇÒÁÃÙŒ ÀÒÂËÅѧ¨Ò¡¼ÙŒ»†ÇµͺẺÊͺ¶ÒÁ¡Òû¯ÔºÑµÔµ¹áÅŒÇ ¡ÒÃÇÔà¤ÃÒÐË¢ŒÍÁÙÅ
¡ÒÃÇÔà¤ÃÒÐËÃдѺ¢Í§¡Òû¯ÔºÑµÔµ¹µÒÁ¤Óá¹Ð¹Ó
¡‹Í¹áÅÐËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 áÅСÒÃÅ´
¡ÒÃἋ¡ÃШÒ¢ͧÃѧÊÕ â´Â¡ÒÃᨡᨧ¤ÇÒÁ¶Õè ÃŒÍÂÅÐ
¡ÒÃÇÔà¤ÃÒÐË¢ŒÍÁÙÅ»˜¨¨Ñ·ÕèÁռŵ‹Í¤ÇÒÁËÇÁÁ×Í㹡ÒÃ
»¯ÔºÑµÔµ¹ÃÐËÇ‹Ò§¡ÒÃÃÑ¡ÉÒâ´Â㪌¡ÒÃÇÔà¤ÃÒÐ˶´¶ÍÂ
¾Ëؤٳ áÅСÒÃà»ÃÕºà·Õº¤Ø³ÀÒ¾ªÕÇԵ㹼ٌ»†ÇÂâä
ÁÐàÃ秵‹ÍÁä·ÃÍ´ ¡‹Í¹-ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹- 131 㪌ʶԵԷÕèäÁ‹ãªŒ¾ÒÃÒÁÔàµÍà ÇÔ¸Õ Wilcoxon signed rank test
¼Å¡ÒÃÈÖ¡ÉÒ
¼ÙŒ»†ÇÂÁÐàÃ秵‹ÍÁä·ÃÍ´áÅÐÂÔ¹ÂÍÁࢌÒËÇÁâ¤Ã§¡Òà 140 ÃÒ ãËŒ¢ŒÍÁÙÅã¹àÃ×èͧ¡Òû¯ÔºÑµÔµ¹¡‹Í¹ÃѺ»Ãзҹ äÍâÍ´Õ¹-131¨Ó¹Ç¹ 140 ÃÒ áÅÐãËŒ¢ŒÍÁÙÅã¹àÃ×èͧ¡ÒÃ
»¯ÔºÑµÔµ¹ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 ¨Ó¹Ç¹ 138 ÃÒ ÍÒÂØ 14-87 »‚ à¾ÈËÞÔ§ ÃŒÍÂÅÐ 79.3 ¹Ñº¶×ÍÈÒʹҾط¸
ÃŒÍÂÅÐ 79.3 ʶҹÀÒ¾¤Ù‹ ÃŒÍÂÅÐ 75 ¨º¡ÒÃÈÖ¡ÉÒ ÃдѺ»ÃжÁÈÖ¡ÉÒ ÃŒÍÂÅÐ 47.9 »ÃСͺÍÒªÕ¾·ÓÊǹ ÃŒÍÂÅÐ 25 ÁÕÃÒÂä´Œµ‹Íà´×͹µèÓ¡Ç‹Ò 10,000 ºÒ· ÃŒÍÂÅÐ 63.6 ÀÒÉÒ·ÕèࢌÒ㨧‹Ò¤×Í ÀÒÉÒ¡ÅÒ§áÅÐÀÒÉÒ㵌 ÃŒÍÂÅÐ 71.4 áÅÐ 83.6 µÒÁÅӴѺ ¨‹Ò¤‹ÒÃÑ¡ÉÒ¾ÂÒºÒÅ â´Â㪌ÊÔ·¸Ôâ¤Ã§¡ÒúѵûÃСѹÊØ¢ÀÒ¾¶ŒÇ¹Ë¹ŒÒ ÃŒÍÂÅÐ
µÒÃÒ§·Õè 1 ¡Òû¯ÔºÑµÔµ¹´ŒÒ¹ÊØ¢ÀÒ¾¡‹Í¹-ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131
¡Òû¯ÔºÑµÔµ¹ ¶Ù¡µŒÍ§ (ÃÒÂ) ÃŒÍÂÅÐ
¡‹Í¹ÃѺ»ÃзҹäÍâÍ´Õ¹-131 (N=140)
äÁ‹ä´ŒÃѺ»ÃзҹÂÒÎÍÃâÁ¹ä·ÃÍ´ÁÒáÅŒÇÍ‹ҧ¹ŒÍ 4 - 6 ÊÑ»´ÒË 138 98.6
äÁ‹ä´ŒÃѺ»ÃзҹÂÒá¡ŒäÍ ÂÒá¡Œ·ŒÍ§àÊÕÂÍ‹ҧ¹ŒÍ 3 Çѹ 137 97.9 äÁ‹ä´ŒÃѺ»ÃзҹÍÒËÒ÷ÐàÅ¡‹Í¹ÁÒÃÑ¡ÉÒÍ‹ҧ¹ŒÍ 3 Çѹ 103 73.6
ÁÒµÃǨµÒÁÇѹ·Õèᾷ¹Ѵ 139 99.3
ä´ŒÁÕ¡ÒäØÁ¡Óà¹Ô´áÅÐäÁ‹ä´ŒÁÕ¡ÒõÑ駤ÃÃÀ 47/54 87
äÁ‹ä´ŒãËŒ¹ÁºØµÃ 10/10 100
ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 àÇÅÒ 1 ÊÑ»´ÒË (N=138)
ÊÃмÁ·Ø¡ÇѹµÑé§áµ‹ÇѹÃѺ»ÃзҹäÍâÍ´Õ¹-131 111 80.4
ÃѺ»ÃзҹÂÒÃкÒ 2 Çѹ¡‹Í¹ÁÒµÃǨ 132 95.7
àÃÔèÁÃѺ»ÃзҹÎÍÃâÁ¹ä·ÃÍ´áÅŒÇ µÒÁÇѹ·Õèá¾·ÂÃÐºØ 133 96.4 ÁÒÃѺ¡ÒõÃǨÊ᡹µÃ§µÒÁÇѹ·Õè˹‹Ç¹Ѵ 137 99.3
64.3 äÁ‹ÁÕâäÍ×è¹Ã‹ÇÁ´ŒÇ ÌÍÂÅÐ 71.4 äÁ‹à¤ÂÁÕ
»ÃÐʺ¡Òó¡ÒÃÃÑ¡ÉÒ ÃŒÍÂÅÐ 52.9 ÀÙÁÔÅÓà¹ÒÍÂÙ‹
µ‹Ò§¨Ñ§ËÇÑ´ ÃŒÍÂÅÐ 78.6 ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131
¨Ðà´Ô¹·Ò§¡ÅѺ仾ѡ·Õ躌ҹ¢Í§µ¹àͧ ÃŒÍÂÅÐ 92.0 â´ÂöʋǹµÑÇ ÃŒÍÂÅÐ 53.6 áÅÐÁÕ¼ÙŒÍ×è¹Ã‹ÇÁà´Ô¹·Ò§´ŒÇ ÁÕÃÐÂйÑè§Ë‹Ò§»ÃÐÁÒ³ 0.1-1 àÁµÃ ÃŒÍÂÅÐ 91.3
àÇÅÒ㹡ÒÃà´Ô¹·Ò§µÑé§áµ‹ 5 ¹Ò·Õ - 2 ªÑèÇâÁ§ ÃŒÍÂÅÐ 50.7 áÅÐàÇÅÒ㹡ÒÃà´Ô¹·Ò§ÁÒ¡¡Ç‹Ò 2 ªÑèÇâÁ§ ÃŒÍÂÅÐ 49.3 ¨Ó¹Ç¹¼ÙŒ»†Ç·ÕèãËŒ¤ÇÒÁËÇÁÁ×Í㹡Òû¯ÔºÑµÔµ¹´ŒÒ¹ ÊØ¢ÀÒ¾¡‹Í¹-ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 áÅСÒÃ
»¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒ¢ͧÃѧÊÕ (µÒÃÒ§·Õè 1-2)
¡Òû¯ÔºÑµÔµ¹ ¶Ù¡µŒÍ§(ÃÒÂ) ÃŒÍÂÅÐ
ᡵÑÇÍÂÙ‹Ë‹Ò§¨Ò¡à´ç¡àÅç¡ 134 97.1
ËÅÕ¡àÅÕ觡ÒáʹËÃ×ÍÍØŒÁ·ÒááÅÐà´ç¡àÅç¡à»š¹àÇÅÒ¹Ò¹æ 134 97.1
äÁ‹ä´Œà¢ŒÒã¡ÅŒÊµÃÕ·ÕèµÑ駤ÃÃÀ 138 100
á¡ˌͧ¹Í¹¤¹à´ÕÂÇ 129 93.5
äÁ‹»˜ÊÊÒÇÐŧ¾×é¹¢³ÐÍÒº¹éÓ 120 87.0
ÃÒ´¹éÓÁÒ¡æ ËÅѧ¶‹Ò»˜ÊÊÒÇÐËÃ×ÍÍب¨ÒÃÐ 136 98.6
´×èÁ¹éÓÁÒ¡æ áÅж‹Ò»˜ÊÊÒÇк‹ÍÂæ 136 98.6
äÁ‹ãªŒÊÔ觢ͧ à¤Ã×èͧ㪌ËÇÁ¡Ñº¼ÙŒÍ×è¹ 130 94.2
äÁ‹«Ñ¡àÊ×éͼŒÒ à¤Ã×èͧ¹Ø‹§Ë‹ÁËÇÁ¡Ñº¼ÙŒÍ×è¹ 131 94.9
ÍÂÙ‹Ë‹Ò§¨Ò¡¼ÙŒÍ×è¹Í‹ҧ¹ŒÍÂÃÐÂÐ 1 àÁµÃ µÅÍ´àÇÅÒ 100 72.5
äÁ‹ä»Ê¶Ò¹·Õèã´æ ·ÕèÁÕ¤¹ËÁÙ‹ÁÒ¡ ઋ¹ µÅÒ´ Èٹ¡ÒäŒÒ ໚¹µŒ¹ 113 81.9 Çѹà´Ô¹·Ò§¡ÅѺ¨Ò¡ÃѺ»ÃзҹäÍâÍ´Õ¹-131 ·‹Ò¹ÍÂÙ‹Ë‹Ò§¨Ò¡¼ÙŒÍ×è¹ 1 àÁµÃ 50 36.2
§´¡ÒÃÁÕà¾ÈÊÑÁ¾Ñ¹¸ 96/98 98.0
ä´ŒÅÒ§Ò¹»ÃШÓà¾×èÍᡵÑÇ 60/75 80.0
§´ãËŒ¹ÁºØµÃÀÒÂã¹ 2 ÊÑ»´ÒËËÅѧÃѺ»Ãзҹ¹éÓäÍâÍ´Õ¹-131 5/6 83.3
¤ØÁ¡Óà¹Ô´â´Â¨ÐÃÐÁÑ´ÃÐÇѧäÁ‹ãËŒÁÕ¡ÒõÑ駤ÃÃÀÀÒÂã¹ 4 à´×͹ËÅѧÃѺ»Ãзҹ¹éÓáË (äÍâÍ´Õ¹-131) 61/65 93.8
µÒÃÒ§·Õè 2 ¡Òû¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 àÇÅÒ 4 Çѹ (N=138)
»˜¨¨Ñ·ÕèÁռŵ‹Í¡Òû¯ÔºÑµÔµ¹ÃÐËÇ‹Ò§¡ÒÃÃÑ¡ÉҢͧ
¼ÙŒ»†ÇÂâäÁÐàÃ秵‹ÍÁä·ÃÍ´ 㪌¡ÒÃÇÔà¤ÃÒÐ˶´¶ÍÂ
¾Ëؤٳ ¤Ó¹Ç³¤Ðá¹¹¾ÄµÔ¡ÃÃÁ¡Òû¯ÔºÑµÔµ¹·Ó â´Â¡Ó˹´ãËŒã¹áµ‹ÅоĵԡÃÃÁÁÕ¹éÓ˹ѡ෋ҡѹ ËÒ¡
¼ÙŒ»†Ç»¯ÔºÑµÔ㹾ĵԡÃÃÁ˹Öè§æ ¶Ù¡µŒÍ§¨Ðä´Œ 1 ¤Ðá¹¹
´Ñ§¹Ñé¹¼ÙŒ»¯ÔºÑµÔµÒÁ¤Óá¹Ð¹Ó¶Ù¡µŒÍ§ 3 ¾ÄµÔ¡ÃÃÁ¨Ðä´Œ 3 ¤Ðá¹¹ ¼Å¡ÒÃÇÔà¤ÃÒÐ˶´¶ÍÂà¾×èÍËÒ»˜¨¨Ñ·ÕèÁռŠµ‹Í¡Òû¯ÔºÑµÔµ¹ÃÐËÇ‹Ò§¡ÒÃÃÑ¡ÉÒ (µÒÃÒ§·Õè 3-4)
Õè 3 ¡ÒÃÇÔà¤ÃÒÐ˶´¶ÍÂà¾×èÍËÒ»˜¨¨Ñ·ÕèÁռŵ‹Í¡Òû¯ÔºÑµÔµ¹¡‹Í¹/ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 µÑÇá»ÃµÒÁ ¤×Í ¡Òû¯ÔºÑµÔµ¹¡‹Í¹/ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 ËÁÒÂà赯 »ÃѺ¤ÇÒÁÃÙŒãËŒ¤Ðá¹¹àµçÁ 100 ÃдѺ¡ÒÃÈÖ¡ÉÒ㪌¡ÅØ‹Á¡ÒÃÈÖ¡ÉÒÃдѺ»ÃжÁÈÖ¡ÉÒ/äÁ‹ä´ŒÃѺ¡ÒÃÈÖ¡ÉÒ à»š¹¡ÅØ‹Á͌ҧÍÔ§ ÃÒÂä´Œµ‹Íà´×͹ 㪌¡ÅØ‹ÁÃÒÂä´Œµ‹Íà´×͹µèÓ¡Ç‹Ò 10,000 ºÒ· ໚¹¡ÅØ‹Á͌ҧÍÔ§ * ËÁÒ¶֧ »˜¨¨Ñ·ÕèÁÕ¤ÇÒÁÊÑÁ¾Ñ¹¸¡Ñº¡Òû¯ÔºÑµÔµ¹¡‹Í¹/ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 Í‹ҧÁÕ¹ÑÂÊÓ¤ÑÞ·Ò§Ê¶ÔµÔ ·ÕèÃдѺ 0.05 B ËÁÒ¶֧ ¤‹ÒÊÑÁ»ÃÐÊÔ·¸Ô춴¶ÍÂẺäÁ‹»ÃѺÁҵðҹ µÑÇá»Ã ¡‹Í¹ÃѺ»Ãзҹ ËÅѧÃѺ»Ãзҹ B Std. Error β t p-value B Std. Error β t p-value ¤ÇÒÁÃÙŒàÃ×èͧ¡Òû¯ÔºÑµÔµ¹ 0.033 0.004 0.569 8.075* <.001 0.012 0.002 0.536 6.637* <.001 »ÃÐʺ¡Òó¡ÒÃÃÑ¡ÉÒ´ŒÇÂäÍâÍ´Õ¹-131 -0.370 0.105 -0.253 -3.531* 0.001 0.009 0.073 0.011 0.136 0.892 ¡ÒÃÈÖ¡ÉÒÃдѺ»ÃÔÞÞÒ¢Öé¹ä» 0.364 0.160 0.194 2.279* 0.024 0.298 0.111 0.258 2.681* 0.008 ¡ÒÃÈÖ¡ÉÒÃдѺÁѸÂÁÈÖ¡ÉÒ/͹ػÃÔÞÞÒ/ÍÒªÕÇÈÖ¡ÉÒ 0.268 0.122 0.165 2.198* 0.030 0.140 0.086 0.139 1.622 0.108 ÃÒÂä´Œµ‹Íà´×͹µÑé§áµ‹ 10,001-20,000 ºÒ· 0.035 0.124 0.021 0.279 0.781 -0.039 0.083 -0.039 -0.475 0.635 ÃÒÂä´Œµ‹Íà´×͹ÁÒ¡¡Ç‹Ò 20,000 ºÒ· 0.130 0.186 0.052 0.699 0.486 -0.017 0.129 -0.011 -0.132 0.895 ¤ÇÒÁÃÙŒàÃ×èͧ¡ÒÃÃÑ¡ÉÒâäÁÐàÃ秵‹ÍÁä·ÃÍ´ 0.000 0.004 0.000 0.003 0.997 - - - - - ¤ÇÒÁÃÙŒ´ŒÒ¹ÊØ¢ÀÒ¾ËÅѧ¡Ô¹äÍâÍ´Õ¹-131 - - - - - 0.000 0.002 0.034 0.420 0.675 ¡ÒÃÃѺÃÙŒ»ÃÐ⪹¢Í§¡Òû¯ÔºÑµÔ 0.015 0.011 0.094 1.277 0.204 0.013 0.013 0.082 1.001 0.319 ¡ÒÃÃѺÃÙŒÍØ»ÊÃä¢Í§¡Òû¯ÔºÑµÔ -0.005 0.059 -0.007 -0.081 0.936 0.062 0.059 0.082 1.048 0.297 ¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹Ã‹Ò§¡Ò 0.018 0.014 0.110 1.271 0.206 0.011 0.008 0.115 1.386 0.169 ¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹Êѧ¤ÁáÅФÃͺ¤ÃÑÇ -0.001 0.014 -0.005 -0.058 0.954 0.013 0.010 0.120 1.363 0.176 ¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹ÍÒÃÁ³ ¨Ôµã¨ 0.0001 0.013 0.003 0.038 0.970 0.018 0.010 0.171 1.787 0.077 ¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹¡Òû¯ÔºÑµÔ¡Ô¨¡ÃÃÁ -0.006 0.013 -0.043 -0.497 0.620 -0.021 0.011 -0.213 -1.925 0.057
µÒÃÒ§·Õè 4 ¡ÒÃÇÔà¤ÃÒÐ˶´¶ÍÂà¾×èÍËÒ»˜¨¨Ñ·ÕèÁռŵ‹Í¡Òû¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕËÅѧÃѺ»Ãзҹ äÍâÍ´Õ¹-131 (N = 138)
µÑÇá»ÃµÒÁ ¤×Í ¡Òû¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 ËÁÒÂà赯 »ÃѺ¤ÇÒÁÃÙŒãËŒ¤Ðá¹¹àµçÁ 100
ÃдѺ¡ÒÃÈÖ¡ÉÒ㪌¡ÅØ‹Á¡ÒÃÈÖ¡ÉÒÃдѺ»ÃжÁÈÖ¡ÉÒ/äÁ‹ä´ŒÃѺ¡ÒÃÈÖ¡ÉÒ à»š¹¡ÅØ‹Á͌ҧÍÔ§
ÃÒÂä´Œµ‹Íà´×͹ 㪌¡ÅØ‹ÁÃÒÂä´Œµ‹Íà´×͹µèÓ¡Ç‹Ò 10,000 ºÒ· ໚¹¡ÅØ‹Á͌ҧÍÔ§
* ËÁÒ¶֧ »˜¨¨Ñ·ÕèÁÕ¤ÇÒÁÊÑÁ¾Ñ¹¸¡Ñº¡Òû¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 Í‹ҧÁÕ¹ÑÂÊÓ¤ÑÞ·Ò§Ê¶ÔµÔ ·ÕèÃдѺ 0.05
B ËÁÒ¶֧ ¤‹ÒÊÑÁ»ÃÐÊÔ·¸Ô춴¶ÍÂẺäÁ‹»ÃѺÁҵðҹ
µÑÇá»Ã B Std. Error β t p-value
¤ÇÒÁÃÙŒÇÔ¸Õ»¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕ 0.192 0.051 0.335 3.758* <0.001
¡ÒÃÈÖ¡ÉÒÃдѺÁѸÂÁÈÖ¡ÉÒáÅÐ͹ػÃÔÞÞÒ/ÍÒªÕÇÈÖ¡ÉÒ 0.446 0.365 0.113 1.221 0.225
¡ÒÃÈÖ¡ÉÒÃдѺ»ÃÔÞÞÒ¢Öé¹ä» 0.790 0.459 0.174 1.722 0.088 ÃÒÂä´Œµ‹Íà´×͹µÑé§áµ‹ 10,001-20,000 ºÒ· -0.109 0.342 -0.027 -0.318 0.751
ÃÒÂä´Œµ‹Íà´×͹ÁÒ¡¡Ç‹Ò 20,000 ºÒ· 0.223 0.530 0.037 0.421 0.675
»ÃÐʺ¡Òó¡ÒÃÃÑ¡ÉÒ´ŒÇÂäÍâÍ´Õ¹-131 -0.366 0.306 -0.103 -1.194 0.235
¤ÇÒÁÃÙŒ¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕ 0.003 0.006 0.048 0.556 0.579 ÃѺÃÙŒ»ÃÐ⪹¢Í§¡Òû¯ÔºÑµÔÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕ -0.014 0.012 -0.118 -1.240 0.218
ÃѺÃÙŒÍØ»ÊÃä¢Í§¡Òû¯ÔºÑµÔ -0.007 0.012 -0.053 -0.581 0.562
¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹Ã‹Ò§¡Ò 0.012 0.033 0.033 0.363 0.717
¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹Êѧ¤ÁáÅФÃͺ¤ÃÑÇ 0.077 0.040 0.178 1.915 0.058
¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹ÍÒÃÁ³ ¨Ôµã¨ 0.034 0.045 0.079 0.755 0.452
¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹¡Òû¯ÔºÑµÔ¡Ô¨¡ÃÃÁ 0.002 0.045 0.006 0.051 0.960
¨Ò¡µÒÃÒ§·Õè 4 ¼Å¡ÒÃÇÔà¤ÃÒÐ˶´¶ÍÂà¾×èÍËÒ
»˜¨¨Ñ·ÕèÁռŵ‹Í¡Òû¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒ ÃѧÊÕËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 ¨ÐàËç¹Ç‹ÒÁÕà¾Õ§»˜¨¨ÑÂ
¤ÇÒÁÃÙŒÇÔ¸Õ»¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕ (p <
0.001) ໚¹»˜¨¨Ñ·ÕèÊ‹§¼Åµ‹Í¡Òû¯ÔºÑµÔµ¹´ŒÒ¹¡ÒÃÅ´
¡ÒÃἋ¡ÃШÒÂÃѧÊÕ
¡ÒÃÈÖ¡ÉҤسÀÒ¾ªÕÇÔµ¢Í§¼ÙŒ»†ÇÂâäÁÐàÃ秵‹ÍÁä·ÃÍ´
¡‹Í¹-ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 (µÒÃÒ§·Õè 5) ¡ÒÃÊÑÁÀÒɳ¤Ø³ÀÒ¾ªÕÇÔµ¼ÙŒ»†ÇÂÀÒÂËÅѧÃѺ»Ãзҹ äÍâÍ´Õ¹-131 ¨Ò¡¤Ó¶ÒÁ»ÅÒÂà»´ 88 ÃÒ ÌÍÂÅÐ 58 ᨌ§Ç‹ÒäÁ‹ÁÕÍÒ¡ÒÃà»ÅÕè¹á»Å§¨Ò¡¡‹Í¹ÃѺ»Ãзҹ äÍâÍ´Õ¹-131 ¼ÙŒ»†Ç¨ӹǹ 58 ÃÒ ÌÍÂÅÐ 42 ᨌ§Ç‹Ò
ÁÕÍÒ¡ÒÃà»ÅÕè¹á»Å§ÀÒÂËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131
¤×Í ¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹Ã‹Ò§¡Ò ÌÍÂÅÐ 42 ¾ºÇ‹Ò¨ÐÁÕ ÍÒ¡ÒûÃÐÁÒ³ 2 ÇѹááËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 áÅÐËÅѧ¨Ò¡¹Ñé¹ÍÒ¡ÒèФ‹ÍÂæ ´Õ¢Öé¹ àª‹¹ »Ç´àÁ×èÍÂ
»Ç´¤Í »Ç´ËÑÇ »Ç´àºŒÒµÒ ¤Å×è¹äÊŒ ÍÒà¨Õ¹ ͋͹à¾ÅÕ ã¨ÊÑè¹ µÖ§ºÃÔàdzÅÓ¤Í ÃŒÍ¹¼‹ÒÇæ µÒÁÅÓµÑÇ áʺ¤Í
¤ÍáËŒ§ à¨çº¤Í ÃÙŒÊ֡ṋ¹·Õè¤ÍáÅÐ˹ŒÒÍ¡ »Ò¡¢Á àº×èÍ- ÍÒËÒÃ
¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹Êѧ¤ÁáÅФÃͺ¤ÃÑÇ ÃŒÍÂÅÐ 6.5 á¡䴌໚¹ 2 ¡ÅØ‹Á ¤×Í ¡ÅØ‹Á·Õè໚¹´ŒÒ¹ºÇ¡ ÃŒÍÂÅÐ 5.8
¤Ãͺ¤ÃÑÇࢌÒã¨áÅÐãËŒ¡ÒôÙáŪ‹ÇÂàËÅ×Í´Õ ¾ºÇ‹Ò¤Ãͺ¤ÃÑÇ
¾Õ蹌ͧãËŒ¡ÓÅѧã¨ÁÒ¡¢Öé¹ ¤Ãͺ¤ÃÑÇ·ÓÍÒËÒÃãˌᵋ¼ÙŒ»†ÇÂ
µÒÃÒ§·Õè 5 ¼Å¡ÒÃà»ÃÕºà·Õº¤Ø³ÀÒ¾ªÕÇÔµ¢Í§¼ÙŒ»†ÇÂâäÁÐàÃ秵‹ÍÁä·ÃÍ´¡‹Í¹áÅÐËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹- 131 (N = 138)
ËÁÒÂà赯 Z ËÁÒ¶֧ ¤‹ÒʶԵԨҡ Wilcoxon signed ranks test
µÑÇá»Ã ¾ÔÊÑ¢ͧ ¡‹Í¹ÃѺ»Ãзҹ ËÅѧÃѺ»Ãзҹ Asmp Sig.
ª‹Ç§¤Ðá¹¹ äÍâÍ´Õ¹-131 äÍâÍ´Õ¹-131 7 Çѹ
¤‹Òà©ÅÕèÂ+ʋǹàºÕè§ູ ¤‹Òà©ÅÕèÂ+ʋǹàºÕè§ູ Z (2-tailed)
Áҵðҹ Áҵðҹ
¤ÇÒÁ¼ÒÊØ¡´ŒÒ¹Ã‹Ò§¡Ò 0 – 28 24.06 + 4.67 23.65 + 4.78 -1.118 0.263
¤ÇÒÁ¼ÒÊØ¡´ŒÒ¹Êѧ¤Á/¤Ãͺ¤ÃÑÇ 0 – 28 22.34 + 4.31 21.83 + 4.01 -2.293 0.022
¤ÇÒÁ¼ÒÊØ¡´ŒÒ¹ÍÒÃÁ³ ¨Ôµã¨ 0 – 24 19.46 + 4.50 19.97 + 4.11 -2.265 0.023
¤ÇÒÁ¼ÒÊØ¡´ŒÒ¹¡Òû¯ÔºÑµÔ¡Ô¨¡ÃÃÁ 0 – 28 18.98 + 5.06 19.49 + 4.89 -1.293 0.196 ÃÇÁ¤ÇÒÁ¼ÒÊØ¡·Ø¡´ŒÒ¹ 0 – 108 84.84 + 12.08 84.94 + 11.75 -0.239 0.811
¨Ðá¡ÃѺ»ÃзҹáÅÐŌҧÀÒª¹Ðàͧ ÅÙ¡áÅÐÊÒÁÕࢌÒã¨
¾ÃŒÍÁ´ÙáÅÅÙ¡àͧ àÅ×͡㪌ÀÒª¹Ð¡Å‹Í§ (â¿Á) ªŒÍ¹-
¾ÅÒʵԡ ʋǹ·Õè໚¹´ŒÒ¹Åº ÃŒÍÂÅÐ 0.7 ¤Ãͺ¤ÃÑÇäÁ‹à¢ŒÒã¨
ÅÙ¡º‹¹Ç‹Ò·ÓäÁࢌÒã¡ÅŒäÁ‹ä´Œ
¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹ÍÒÃÁ³ ¨Ôµã¨ ¼ÙŒ»†ÇÂÃŒÍÂÅÐ 9.4 ÁÕ¤ÇÒÁ¡Ñ§ÇÅ㨠·ŒÍ㨠ÌͧäËŒàÁ×èÍÍÂÙ‹¤¹à´ÕÂÇ à¤ÃÕ´·Õè ÃÙŒÊ֡Njҷӧҹ䴌¹ŒÍÂŧ ºÒ§ÃÒ¤Դ¿Ø‡§«‹Ò¹áÅйŒÍÂã¨
µÑÇàͧNjҷÕèä»ä˹ÁÒä˹äÁ‹ä´Œà¾ÃÒл†ÇÂ໚¹âä¹Õé ¼ÙŒ»†ÇÂ
·Õè໚¹¹Ñ¡àÃÕ¹¹Ñ¡ÈÖ¡ÉÒºÍ¡Ç‹Ò ¡ÒÃËÂØ´àÃÕ¹ ·ÓãËŒ¡ÅÑÇ àÃÕ¹äÁ‹·Ñ¹à¾×è͹
¤ÇÒÁ¼ÒÊØ¡·Ò§´ŒÒ¹¡Òû¯ÔºÑµÔ¡Ô¨¡ÃÃÁ ¼ÙŒ»†ÇÂÃŒÍÂÅÐ 6.5 ¤Ô´ÁÒ¡ ¹Í¹äÁ‹ËÅѺ ¡Ñ§ÇÅàÃ×èͧ¡Ò÷ӧҹà¾ÃÒÐ ËÂØ´§Ò¹ËÅÒÂÇѹ
ÇÔ¨Òó
¡ÒÃÈÖ¡ÉÒʹѺʹعá¹Ç¤Ô´ÃٻẺ¡ÒÃÊ‹§àÊÃÔÁ ÊØ¢ÀÒ¾¢Í§ Pender áÅФ³Ð4 ·Õè¡Å‹ÒÇÇ‹ÒÁâ¹·ÑȹËÅÑ¡
¢Í§áºº¨ÓÅͧ «Ö觻ÃСͺ´ŒÇ »ÃÐʺ¡Òó áÅÐ
¤Ø³ÅѡɳТͧ»˜¨à¨¡ºØ¤¤Å ÍÒÃÁ³áÅСÒäԴÃÙŒ·Õè੾ÒÐ à¨ÒШ§¡Ñº¾ÄµÔ¡ÃÃÁ áÅмÅÅѾ¸´ŒÒ¹¾ÄµÔ¡ÃÃÁ ÁÕÍÔ·¸Ô¾Å µ‹Í¾ÄµÔ¡ÃÃÁÊ‹§àÊÃÔÁÊØ¢ÀÒ¾ ´Ñ§¹Ñé¹ ¡Ò÷Õè¨ÐãËŒ¼ÙŒ»†ÇÂÁÕ
¤ÇÒÁËÇÁÁ×Í㹡Òû¯ÔºÑµÔµ¹ÃÐËÇ‹Ò§¡ÒÃÃÑ¡ÉÒ Ë¹‹Ç§ҹ¤Çà ์¹ä»ãËŒ¤ÇÒÁÃÙŒã¹àÃ×èͧÇÔ¸Õ¡Òû¯ÔºÑµÔµ¹´ŒÒ¹ÊØ¢ÀÒ¾ áÅÐ
¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕá¡‹¡ÅØ‹Á¼ÙŒ»†Ç·ÕèÁÕ¡ÒÃÈÖ¡ÉÒ ÃдѺµèÓ¡Ç‹ÒÁѸÂÁÈÖ¡ÉÒãËŒÁÒ¡¡Ç‹Ò¡ÅØ‹Á¼ÙŒ»†Ç·ÕèÁÕ
¡ÒÃÈÖ¡ÉÒÍ×è¹
¼Å¡ÒÃà»ÃÕºà·Õº¤Ø³ÀÒ¾ªÕÇÔµ¢Í§¼ÙŒ»†ÇÂÁÐàÃç§
µ‹ÍÁä·ÃÍ´¡‹Í¹áÅÐËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 ¼ÙŒ»†Ç ÁÕ¤Ðá¹¹à©ÅÕè¤سÀÒ¾ªÕÇÔµ·Ø¡´ŒÒ¹¤‹Í¹¢ŒÒ§ÊÙ§ ¼Å¡Òà ÇÔà¤ÃÒÐ˾ºÇ‹Ò¤ÇÒÁ¼ÒÊØ¡´ŒÒ¹Êѧ¤Á/¤Ãͺ¤ÃÑÇŴŧ
ᵋ¤ÇÒÁ¼ÒÊØ¡´ŒÒ¹ÍÒÃÁ³ ¨Ôµã¨à¾ÔèÁ¢Öé¹Í‹ҧÁÕ¹ÑÂÊÓ¤ÑÞ
·Ò§Ê¶ÔµÔ·ÕèÃдѺ 0.05 ¡ÒÃÇÑ´¤Ø³ÀÒ¾ªÕÇÔµ¢Í§·Ñé§ 2 ª‹Ç§
໚¹ª‹Ç§àÇÅÒ·Õè¼ÙŒ»†ÇÂÍÂÙ‹ã¹ÀÒÇТҴÎÍÃâÁ¹ä·ÃÍ´
ÊÙ§ÊØ´ ¤ÇÒÁà»ÅÕè¹á»Å§·Ò§´ŒÒ¹Ã‹Ò§¡Ò¨֧à»ÅÕè¹á»Å§
äÁ‹ÁÒ¡¹Ñ¡«Öè§äÁ‹Ê‹§¼ÅãËŒ¤Ø³ÀÒ¾ªÕÇÔµ´ŒÒ¹Ã‹Ò§¡ÒÂÁÕ¤ÇÒÁ ᵡµ‹Ò§¡Ñ¹Í‹ҧÁÕ¹ÑÂÊÓ¤Ñ޷ҧʶԵԷÕèÃдѺ 0.05 ÊÓËÃѺ
¡ÒÃᡵÑÇàͧ¨Ò¡¼ÙŒÍ×è¹à¾×èÍËÅÕ¡àÅÕ觡ÒÃἋ¡ÃШÒ ÃѧÊÕ 5-7 Çѹ ·ÓãËŒÇÔ¶ÕªÕÇÔµ¢Í§¼ÙŒ»†Ç»ÃѺà»ÅÕè¹ä»
Ê‹§¼ÅãËŒ¤ÇÒÁ¼ÒÊØ¡´ŒÒ¹Êѧ¤Á/¤Ãͺ¤ÃÑÇŴŧÍ‹ҧÁÕ
¹ÑÂÊÓ¤ÑÞ·Ò§Ê¶ÔµÔ 0.05 ¡ÒÃÊÑÁÀÒɳ¼ÙŒ»†Ç¤ÃÑ駷Õè 1 ¼ÙŒÇԨѫÖè§à»š¹ºØ¤ÅÒ¡Ãã¹Ë¹‹ÇÂàǪÈÒʵùÔÇà¤ÅÕÂÃ
âç¾ÂÒºÒÅʧ¢ÅÒ¹¤ÃÔ¹·Ã à»´âÍ¡ÒÊãËŒ¼ÙŒ»†ÇÂä´Œ«Ñ¡¶ÒÁ
¢ŒÍʧÊÑÂà¡ÕèÂǡѺ¼Å¡Ãзºµ‹Ò§æ ·Õèà¡Ô´¢Ö鹨ҡ¡ÒÃÃÑ¡ÉÒ
«Ö觼ٌÇÔ¨ÑÂàª×èÍÇ‹Ò¡Ò÷Õè¼ÙŒ»†ÇÂä´ŒÃѺ¤Ó͸ԺÒ¢ŒÍʧÊÑ ËÃ×Í
¤ÇÒÁÇÔµ¡¡Ñ§ÇÅ仨зÓãËŒ¼ÙŒ»†Ç¤ÅÒ¤ÇÒÁ¡Ñ§ÇÅàÃ×èͧ
à¨çº»†ÇÂä»ä´ŒÃдѺ˹Öè§ Ê‹§¼ÅãËŒ¤Ðá¹¹à©ÅÕè¤سÀÒ¾ ªÕÇԵ㹴ŒÒ¹ÍÒÃÁ³ ¨Ôµã¨´Õ¢Öé¹ à»š¹¼ÅãËŒÁÕ¤ÇÒÁᵡµ‹Ò§
¡Ñ¹Í‹ҧÁÕ¹ÑÂÊÓ¤Ñ޷ҧʶԵԷÕèÃдѺ 0.05 ʋǹ¡ÒÃ
»¯ÔºÑµÔ¡Ô¨¡ÃÃÁ¢Í§¼ÙŒ»†Ç·Ñé§ 2 ª‹Ç§ ¼ÙŒ»†ÇÂÂѧÍÂÙ‹ã¹ ÀÒÇТҴÎÍÃâÁ¹ä·ÃÍ´ÊÙ§ÊØ´ ·ÓãËŒÊÀҾËҧ¡Ò ÂѧäÁ‹¾ÃŒÍÁ㹡Òû¯ÔºÑµÔ¡Ô¨¡ÃÃÁ ¤ÇÒÁà»ÅÕè¹á»Å§
·Õèà¡Ô´¢Öé¹äÁ‹ÁÒ¡¾Í·Õè¨ÐÊ‹§¼ÅãËŒà¡Ô´¤ÇÒÁᵡµ‹Ò§¡Ñ¹ Í‹ҧÁÕ¹ÑÂÊÓ¤Ñ޷ҧʶԵԷÕèÃдѺ 0.05 ¼ÙŒÇÔ¨ÑÂä´Œ¹Ó
¼Å¡ÒÃÇÔà¤ÃÒÐË¡ÒÃÇÑ´¤Ø³ÀÒ¾ªÕÇÔµ¤ÃÑ駷Õè 2 «Öè§à»š¹ª‹Ç§
ËÅѧÃѺ»ÃзҹäÍâÍ´Õ¹-131 áÅÐàÃÔèÁÎÍÃâÁ¹ä·ÃÍ´ 2-3 Çѹ «Öè§ÁÕ¤Ðá¹¹à©ÅÕèµèÓÊØ´¢Í§·Ø¡´ŒÒ¹à·‹Ò¡Ñº 19.97
¤Ðá¹¹à©ÅÕèÂÊÙ§ÊØ´ 23.65 ä»à»ÃÕºà·Õº¡Ñº¼Å¡Òà ÇÔà¤ÃÒÐˤسÀÒ¾ªÕÇÔµ¤ÃÑ駷Õè 2 ¢Í§¼ÙŒ»†ÇÂ㹡ÒÃÇԨѢͧ
Dow áÅФ³Ð5 ä´Œ·Ó¡ÒÃÈÖ¡ÉÒ¡ÒÃà»ÅÕè¹á»Å§¢Í§
¤Ø³ÀÒ¾ªÕÇԵ㹼ٌ»†ÇÂÁÐàÃ秵‹ÍÁä·ÃÍ´ËÅѧ¨Ò¡ËÂØ´
ÎÍÃâÁ¹ä·ÃÍ´à¾×èÍàµÃÕÂÁµÑÇÁÒµÃǨÊ᡹·Ñ駵ÑÇ ¤Ðá¹¹ à©ÅÕèµèÓÊØ´¢Í§·Ø¡´ŒÒ¹à·‹Ò¡Ñº 15.72 ¤Ðá¹¹à©ÅÕèÂÊÙ§ÊØ´
19.67 ¾ºÇ‹Ò¼ÙŒ»†Ç¢ͧ§Ò¹ÇԨѤÃÑ駹Õé (¼ÙŒ»†Ç¢ͧ˹‹Ç àǪÈÒʵùÔÇà¤ÅÕÂà âç¾ÂÒºÒÅʧ¢ÅÒ¹¤ÃÔ¹·Ã) ÁÕ
¤Ø³ÀÒ¾ªÕÇÔµÁÒ¡¡Ç‹Ò¢Í§ Dow áÅФ³Ð
͹Öè§ ã¹¡ÒÃÈÖ¡ÉÒ¤ÃÑ駹ÕéäÁ‹ä´ŒÊÑÁÀÒɳ¤Ø³ÀÒ¾ªÕÇÔµ
¼ÙŒ»†Ç¡‹Í¹ÃѺ»ÃзҹäÍâÍ´Õ¹-131 ÁÒ¡‹Í¹à¾×èÍ໚¹
¾×é¹°Ò¹¢Í§¼ÙŒ»†ÇÂᵋÅÐÃÒ ¨Ö§äÁ‹ÊÒÁÒöÊÃػ䴌ªÑ´à¨¹ Ç‹Ò»˜ÞËÒ ËÃ×ͼšÃзº·Õèà¡Ô´¢Öé¹ÀÒÂËÅѧÃѺ»Ãзҹ äÍâÍ´Õ¹-131 ¤×ͼšÃзº·Õèà¡Ô´¨Ò¡¡ÒÃÃѺ»Ãзҹ äÍâÍ´Õ¹-131 à¾Õ§Í‹ҧà´ÕÂÇ㪋ËÃ×ÍäÁ‹
ÊÃØ»
¼ÙŒ»†ÇÂÁÐàÃ秵‹ÍÁä·ÃÍ´ãËŒ¤ÇÒÁËÇÁÁ×Í㹡Òû¯ÔºÑµÔµ¹ÃÐËÇ‹Ò§¡ÒÃÃÑ¡ÉÒ໚¹Í‹ҧ´Õ ¡àÇŒ¹
¾ÄµÔ¡ÃÃÁ¡ÒÃÅ´¡ÒÃἋ¡ÃШÒÂÃѧÊÕ㹺ҧ»ÃÐà´ç¹
»˜¨¨Ñ·ÕèÁÕ¤ÇÒÁÊÑÁ¾Ñ¹¸¡Ñº¡Òû¯ÔºÑµÔµ¹ÃÐËÇ‹Ò§
¡ÒÃÃÑ¡ÉÒ ¤×Í ¤ÇÒÁÃÙŒàÃ×èͧÇÔ¸Õ¡Òû¯ÔºÑµÔµ¹ áÅСÒà ÈÖ¡ÉÒ˹‹Ç§ҹ¤ÇÃ์¹ãËŒ¤ÇÒÁÃÙŒã¹àÃ×èͧÇÔ¸Õ¡ÒÃ
»¯ÔºÑµÔµ¹´ŒÒ¹ÊØ¢ÀÒ¾ áÅСÒÃÅ´¡ÒÃἋ¡ÃШÒ ÃѧÊÕá¡‹¡ÅØ‹Á¼ÙŒ»†Ç·ÕèÁÕ¡ÒÃÈÖ¡ÉÒÃдѺµèÓ¡Ç‹ÒÁѸÂÁ ÈÖ¡ÉÒãËŒÁÒ¡¡Ç‹Ò¡ÅØ‹Á¼ÙŒ»†Ç·ÕèÁÕ¡ÒÃÈÖ¡ÉÒÍ×è¹æ à¾×èÍãËŒ¼ÙŒ»†ÇÂÁվĵԡÃÃÁ·ÕèàËÁÒÐÊÁÁÒ¡¢Öé¹
àÍ¡ÊÒÃ͌ҧÍÔ§
1. Prechawittayakul P. Hospital – based cancer regis- try Songklanagarind Hospital 2006. Songkhla:
Songklanagarind Cancer Center, Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University; 2008.
2. ÊÁÒ¤ÁàǪÈÒʵùÔÇà¤ÅÕÂÃáË‹§»ÃÐà·Èä·Â. ÊÁÒ¤Á¹Ñ¡¿ÊÔ¡Ê
¡ÒÃá¾·Âä·Â áÅÐÊӹѡ§Ò¹¾Åѧ§Ò¹»ÃÁÒ³Ùà¾×èÍÊѹµÔ.
Radiation safety management in nuclear medicine.
¡Ãا෾ÁËÒ¹¤Ã: ¾Õ.àÍ.ÅÕ¿ÇÔè§; 2549.
3. Ratanatharathorn V, Sirilerttrakul S, Jirajarus M, et al. Quality of life, functional assessment of cancer therapy-general. J Med Assoc Thai 2001;84:
1430-42.
4. Pender NJ, Murdaugh CL, Parsons MA. Health promotion in nursing practice. 4th ed. New Jersey:
Pearson Education Inc; 2002.
5. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-9.
